What's Going On With Hims & Hers Health Shares Monday? - Hims & Hers Health ( NYSE:HIMS )
Shares of Hims & Hers Health Inc ( NYSE:HIMS ) are trading marginally lower Monday morning, as competitive news overshadows bullish announcements from the company. Here's what investors need to know. HIMS is facing resistance from sellers. Get the market research here.
How Did Tempus AI Power Its Move to Positive EBITDA in Q3?
TEM hits its first positive adjusted EBITDA as strong Genomics and Data Licensing growth pairs with tighter cost discipline.
Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing - Hims & Hers Health ( NYSE:HIMS )
Hims & Hers Health, Inc. ( NYSE:HIMS ) announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it. Labs measures key markers over time and provides doctor-developed action plans.
Here's Why Quest Diagnostics ( DGX ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics ( DGX ) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Guardant Health Stock Surged Today
The healthcare company's innovative cancer tests are helping to save lives.
Guardant Health ( GH ) Q3 2025 Earnings Transcript
Image source: The Motley Fool.Wednesday, Oct. 29, 2025 at 4:30 p.m. ETCo-Chief Executive Officer - Helmy EltoukhyContinue reading ...
Why Quest Diagnostics ( DGX ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Price Over Earnings Overview: Quest Diagnostics - Quest Diagnostics ( NYSE:DGX )
In the current market session, Quest Diagnostics Inc. ( NYSE:DGX ) share price is at $183.60, after a 0.20% increase. Moreover, over the past month, the stock fell by 3.65%, but in the past year, increased by 16.79%.
Quest Diagnostics Analysts Increase Their Forecasts After Q3 Earnings - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics ( NASDAQ:DGX ) posted better-than-expected earnings for the third quarter on Tuesday. While Quest Diagnostics raised its revenue and adjusted earnings guidance for full-year 2025, the company lowered its GAAP earnings per share guidance to a range of $8.58 to $8.66 from a ...
Here's Why Quest Diagnostics ( DGX ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics Reports Q3 Earnings, Shares Slide - Quest Diagnostics ( NYSE:DGX )
Shares of Quest Diagnostics ( NASDAQ:DGX ) are falling Tuesday after the medical laboratories company shared mixed earnings results. DGX is feeling the pressure from bearish momentum. See the trading setup here.
Gold Sinks 5% On Worst Day In 5 Years, Dow Jones Hits Record Highs - VanEck Gold Miners ETF ( ARCA:GDX )
Gold prices suffered a sharp correction on Tuesday as investors locked in profits following this year's explosive rally, while optimism across earnings kept industrial stocks powering higher and pushed the Dow Jones to fresh record highs.
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DGX posts a strong Q3 with revenues and EPS beating estimates, higher margins and an upbeat full-year outlook.
Quest Diagnostics ( DGX ) Surpasses Q3 Earnings and Revenue Estimates
Quest Diagnostics (DGX) delivered earnings and revenue surprises of +3.59% and +3.45%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Tempus AI Fuels Growth Through Strategic Biotech Collaborations
TEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.
Will Quest Diagnostics ( DGX ) Beat Estimates Again in Its Next Earnings Report?
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics ( DGX ) Reports Next Week: Wall Street Expects Earnings Growth
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
DGX is poised for solid Q3 2025 results, backed by strong DIS growth, strategic M&A and robust test demand across key health segments.
Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus
MariMed, Xeris Biopharma and Lam Research shine as Zacks' proven stock strategies continue to beat the market despite turmoil.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Quest Diagnostics ( DGX ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing
DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.
DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Addus HomeCare and The Pennant
Quest Diagnostics, DaVita, Addus HomeCare, and The Pennant Group are positioned to benefit from telehealth, AI adoption, and rising demand in the $747B home healthcare market.
4 Outpatient Home Health Stocks Worth Watching Amid Shifting Trends
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.
Here's Why Quest Diagnostics ( DGX ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration - Quest Diagnostics ( NYSE:DGX )
SECAUCUS, N.J., Sept. 23, 2025 /PRNewswire/ -- Quest Diagnostics DGX and Epic today announced a first-of-its-kind collaboration designed to streamline and improve experiences for healthcare providers and patients that engage Quest for laboratory testing in the United States.
Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?
DGX posts strong gains from physician and hospital channels while advancing AI-powered solutions.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Payscale Acquires AI-Powered Recruiting Platform Datapeople, Creating Alignment Between Talent Acquisition and Compensation
BOSTON, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- Payscale Inc., the leading provider of compensation intelligence solutions, announced today that it has acquired Datapeople, an AI-powered recruiting platform that helps hiring teams create clearer, more effective, and more compliant job postings.
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs
EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
Should You Continue to Hold EXAS Stock in Your Portfolio?
Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.
Quest Diagnostics: A Solid Investment or a Risky Bet?
Join us as we analyze Quest Diagnostics and uncover whether this lab giant is a smart investment choice for the future. With insights from industry experts, you won't want to miss this evaluation!
Encompass Health ( EHC ) Up 8.6% Since Last Earnings Report: Can It Continue?
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Quest Diagnostics ( DGX ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Is Chemed ( CHE ) Up 9.3% Since Last Earnings Report?
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics ( DGX ) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DGX Stock Gains Following a New Joint Venture With Corewell Health
Quest Diagnostics shares rise after forming a joint venture with Corewell Health to expand advanced lab services across Michigan.
This Quest Diagnostics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Quest Diagnostics ( NYSE:DGX ) , American Eagle Outfitters ( NYSE:AEO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. DA Davidson analyst Matt Summerville downgraded Symbotic Inc.
Why Is Quest Diagnostics ( DGX ) Up 8.2% Since Last Earnings Report?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Quest Diagnostics Stock Be in Your Portfolio Right Now?
DGX drives growth with advanced diagnostics, acquisitions and cost savings, but rising debt and macro risks weigh on its outlook.
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
HOLX's Genius digital cytology system and global rollout position its Cytology unit for long-term growth despite near-term headwinds.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MedWellAi, Inc Joins Trump Mobile In Engaging BrighterMD To Develop Ai-Inhanced Healthcare Telemedicine Platform, Focused On $24.46 Billion Corporate Wellness Market - MedWellAI ( OTC:MWAI )
CLEARWATER, Fla., Aug. 18, 2025 /PRNewswire/ -- MedWell Ai, Inc, ( "Company" ) MWAI is pleased to confirm the collaboration and execution of Software Development Agreement with BrighterMD, to develop and launch Company's latest initiative: TeleMD.Ai - Nationwide B2B and B2C Healthcare and ...
Here's Why Quest Diagnostics ( DGX ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What Does the Market Think About Quest Diagnostics? - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics's DGX short percent of float has risen 3.64% since its last report. The company recently reported that it has 4.74 million shares sold short, which is 4.84% of all regular shares that are available for trading.
OraSure Appoints Anne Messing as Chief Commercial Officer
BETHLEHEM, Pa., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- OraSure Technologies, Inc. ( "OTI" ) ( NASDAQ: OSUR ) , a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.
